Investors
In June 2020, we secured a $55 million Series B financing round led by Novo Ventures. The round included Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and founding investor Epidarex Capital.
In June 2018, we completed a $40 million Series A financing in led by Sofinnova Partners and 5AM Ventures, with participation from Epidarex Capital and F-Prime Capital.
The support of these investors is a testament to not only the strength of our science and management team, but also to the significant market opportunity in the NLRP3 inflammasome space.
© 2022 Tavotek medical All rights reserved. 苏ICP备13000009号-1
© 2021 Tavotek medical. All rights reserved. 苏ICP备20001100号-1